BioPharma DiveOriginal article
Tyra disappoints investors with bladder cancer data
Phase 2negativeNegative
AI Analysis
Summary
Tyra's Phase 2 bladder cancer trial showed remission rates that missed Wall Street expectations. Some analysts expect improved results in late-stage testing.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Remission rates fell short of Wall Street expectations
Importance:6/10
Sentiment:
-0.70
Phase 2bladder cancerdisappointing resultsremission rates
Related Companies
Read the original article
Published by BioPharma Dive on September 9, 2026 7:46 PM